Financial Technology

Financial Technology - INDUSTRY NEWS

Share

TMCNet:  Research and Markets: Triple Analysis: Lung Cancer, Lymphoma and Antibodies

[January 03, 2013]

Research and Markets: Triple Analysis: Lung Cancer, Lymphoma and Antibodies

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/6x9mpn/triple_analysis) has announced the addition of the "Triple Analysis: Lung Cancer, Lymphoma and Antibodies" report to their offering.

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Synopsis (News - Alert)

I: Lung Cancer

The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different copound strategies and and three subindications of lung cancer.

Story continues below ↓

II: Lymphoma

The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.

III: Antibodies

The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.

Reasons To Buy

The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

- Supporting development of integrative molecule, pathway and disease area strategies

- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

For more information visit http://www.researchandmarkets.com/research/6x9mpn/triple_analysis


[ Back To Financial Technology's Homepage ]